Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer

Publisher： Karger

E-ISSN： 2296-5262|28|11|573-578

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.28, Iss.11, 2005-10, pp. : 573-578

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 7, 2007-06 ,pp. : 355-360

Karger

Access to resources Recommend Favorite

Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

By Yasufuku Tomihiko   Shigemura Katsumi   Matsumoto Osamu   Arakawa Soichi   Fujisawa Masato  

Journal of Infection and Chemotherapy, Vol. 16, Iss. 3, 2010-06 ,pp. : 200-205

Springer Publishing Company

Access to resources Recommend Favorite

Prospective Study of Estramustine Phosphate for Hormone Refractory Prostate Cancer Patients following Androgen Deprivation Therapy

By  

Urologia Internationalis, Vol. 75, Iss. 1, 2005-07 ,pp. : 43-49

Karger

Access to resources Recommend Favorite

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 281-287

Karger

Access to resources Recommend Favorite

Phase II Study of Repeated Single 24-Hour Infusion of Low-Dose 5-Fluorouracil for Palliation in Symptomatic Hormone-Refractory Prostate Cancer

By  

Urologia Internationalis, Vol. 69, Iss. 4, 2002-11 ,pp. : 273-277

Karger

Access to resources Recommend Favorite